Skip to main content

Table 2 Summary of Adverse Events Occurring in Patients With and Without Allodynia

From: Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

  With Allodynia
(n = 290)
Without Allodynia
(n = 426)
AEs, n (%)
  ≥ 1 AE 185 (63.8) 251 (58.9)
 Serious AE 36 (12.4) 39 (9.2)
 Discontinuation due to AE 14 (4.8) 18 (4.2)
TRAEs, n (%)
  ≥ 1 TRAE 56 (19.3) 75 (17.6)
TRAEs occurring in ≥1% of either subgroup
 Neck pain 15 (5.2) 14 (3.3)
 Eyelid ptosis 6 (2.1) 12 (2.8)
 Musculoskeletal stiffness 6 (2.1) 11 (2.6)
 Headache 6 (2.1) 6 (1.4)
 Injection site pain 5 (1.7) 9 (2.1)
 Facial paresis 4 (1.4) 5 (1.2)
 Muscular weakness 3 (1.0) 7 (1.6)
 Migraine 3 (1.0) 4 (0.9)
 Injection site hematoma 3 (1.0) 1 (0.2)
 Muscle spasms 3 (1.0) 1 (0.2)
 Skin tightness 1 (0.3) 6 (1.4)
  1. AE adverse event, TRAE treatment-related adverse event
\